28 results on '"Vachier, Isabelle"'
Search Results
2. Sputum rheology measurements in chronic respiratory diseases are similar across specialist centres
- Author
-
Tavernier, Gaël, primary, Qureshi, Taqdees, additional, Volpato, Mathilde, additional, Vachier, Isabelle, additional, Wood, Marion, additional, Zurel, Furkan, additional, Thornton, David, additional, Robert De Saint Vincent, Matthieu, additional, Patarin, Jeremy, additional, Lord, Robert, additional, Fowler, Stephen, additional, and Charriot, Jeremy, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Late Breaking Abstract - Development of a bronchial epithelium with a sensory innervation both derived from induced pluripotent stem cells
- Author
-
FOISSET, FLORENT, primary, Lehalle, Christine, additional, Nasri, Amel, additional, Bourdais, Carine, additional, Morichon, Lisa, additional, Vachier, Isabelle, additional, Assou, Said, additional, Bourdin, Arnaud, additional, De Vos, John, additional, and Frossard, Nelly, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Benefits of bronchial epithelial repair by iPSC in COPD
- Author
-
Nadaud, Marion, primary, Bourdais, Carine, additional, Fort-Petit, Aurélie, additional, De Vos, John, additional, Hireche, Kheira, additional, Vachier, Isabelle, additional, Ahmed, Engi, additional, and Bourdin, Arnaud, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Sputum viscosity is correlated with Computed Tomography (CT) mucus score in muco-obstructive lung diseases
- Author
-
Charriot, Jérémy, primary, Petit, Aurélie, additional, Suehs, Carey, additional, Patarin, Jérémy, additional, Matzner-Lober, Eric, additional, Vachier, Isabelle, additional, Molinari, Nicolas, additional, and Bourdin, Arnaud, additional
- Published
- 2023
- Full Text
- View/download PDF
6. Construction of a 3D innervated bronchial epithelium from human induced pluripotent stem cells iPSC
- Author
-
Foisset, Florent, primary, Lehalle, Christine, additional, Nasri, Amel, additional, Vachier, Isabelle, additional, Assou, Said, additional, Muller, Quentin, additional, Flacher, Vincent, additional, Bourdin, Arnaud, additional, De Vos, John, additional, and Frossard, Nelly, additional
- Published
- 2022
- Full Text
- View/download PDF
7. Role of stromal cells during human iPSC differentiation into bronchial epithelium
- Author
-
Nasri, Amel, primary, Foisset, Florent, additional, Ahmed, Engi, additional, Vachier, Isabelle, additional, Assou, Said, additional, Bourdin, Arnaud, additional, and De Vos, John, additional
- Published
- 2021
- Full Text
- View/download PDF
8. Late Breaking Abstract - Biological determinants of sputum rheology in chronic airway diseases
- Author
-
Volpato, Mathilde, primary, Vialaret, Jérôme, additional, Hirtz, Christophe, additional, Suehs, Carey, additional, Matzner-Lober, Eric, additional, Vachier, Isabelle, additional, Molinari, Nicolas, additional, Bourdin, Arnaud, additional, and Charriot, Jeremy, additional
- Published
- 2020
- Full Text
- View/download PDF
9. Mucus rheology and ciliary beating coordination
- Author
-
Jory, Myriam, primary, Blanc, Christophe, additional, Fort, Aurélie, additional, Casanellas, Laura, additional, Vachier, Isabelle, additional, Bourdin, Arnaud, additional, and Massiera, Gladys, additional
- Published
- 2018
- Full Text
- View/download PDF
10. Differentiation of Induced Pluripotent Stem Cells (iPSC) into human bronchial epithelium from healthy and severe COPD patients.
- Author
-
Ahmed, Engi, primary, Assou, Said, additional, Fieldes, Mathieu, additional, Vachier, Isabelle, additional, Chanez, Pascal, additional, De Vos, John, additional, and Bourdin, Arnaud, additional
- Published
- 2018
- Full Text
- View/download PDF
11. Club cells in histological patterns of interstitial lung diseases
- Author
-
Reynaud, Paul, primary, Serre, Isabelle, additional, Vachier, Isabelle, additional, Fort, Aurélie, additional, Vernisse, Charlotte, additional, Romagnoli, Micaela, additional, Durand, Gérard, additional, Cabon, Yann, additional, Bommart, Sébastien, additional, Gamez, Anne-Sophie, additional, and Bourdin, Arnaud, additional
- Published
- 2018
- Full Text
- View/download PDF
12. Supervising differentiation for tailoring the airway epithelial cell phenotype
- Author
-
Vernisse, Charlotte, primary, Drappier, Noemie, additional, Fort, Aurelie, additional, Knabe, Lucie, additional, Vachier, Isabelle, additional, Gras, Delphine, additional, Chanez, Pascal, additional, Ahmed, Engi, additional, and Bourdin, Arnaud, additional
- Published
- 2018
- Full Text
- View/download PDF
13. Quality of life in worsening and non-worsening PAH patient's in a 1 year follow-up: What's going on?
- Author
-
Halimi, Laurence, primary, Molinari, Nicolas, additional, Marin, Gregory, additional, Gamez, Anne Sophie, additional, Boissin, Clement, additional, Vachier, Isabelle, additional, and Bourdin, Arnaud, additional
- Published
- 2015
- Full Text
- View/download PDF
14. Effect of whole cigarette smoke exposure and CCSP on MUC5AC mucin production in primary cultures of human bronchial epithelial cells at air-liquid interface of COPD, smokers and control patients
- Author
-
Charriot, Jérémy, primary, Petit, Aurélie, additional, Knabe, Lucie, additional, Anne-Sophie, Gamez, additional, Vachier, Isabelle, additional, and Bourdin, Arnaud, additional
- Published
- 2015
- Full Text
- View/download PDF
15. Cellular mechanisms underlying CCSP SNP association with chronic airway diseases
- Author
-
Knabe, Lucie, primary, Bonini, Jennifer, additional, Varilh, Jessica, additional, Aurélie, Petit, additional, Vachier, Isabelle, additional, Chanez, Pascal, additional, Taulan, Magali, additional, and Bourdin, Arnaud, additional
- Published
- 2015
- Full Text
- View/download PDF
16. TSPO a new anti-inflammatory target in the airway of COPD
- Author
-
Jean, Romain, primary, Bribes, Estelle, additional, Knabe, Lucie, additional, Fort-Petit, Aurélie, additional, Vachier, Isabelle, additional, Chanez, Pascal, additional, and Bourdin, Arnaud, additional
- Published
- 2015
- Full Text
- View/download PDF
17. Asthma: treatment and prevention of pulmonary exacerbations
- Author
-
Charriot, Jérémy, primary, Volpato, Mathilde, additional, Sueh, Carey, additional, Boissin, Clément, additional, Gamez, Anne Sophie, additional, Vachier, Isabelle, additional, Halimi, Laurence, additional, Chanez, Pascal, additional, and Bourdin, Arnaud, additional
- Full Text
- View/download PDF
18. The effect of the COVID-19 pandemic on severe asthma care in Europe: will care change for good?
- Author
-
Eger K, Paroczai D, Bacon A, Schleich F, Sergejeva S, Bourdin A, Vachier I, Zervas E, Katsoulis K, Papapetrou D, Kostikas K, Csoma Z, Heffler E, Canonica GW, Grisle I, Bieksiene K, Palacionyte J, Ten Brinke A, Hashimoto S, Smeenk FWJM, Braunstahl GJ, van der Sar S, Mihălţan F, Nenasheva N, Peredelskaya M, Zvezdin B, Čekerevac I, Hromiš S, Ćupurdija V, Lazic Z, Milenkovic B, Dimic-Janjic S, Yasinska V, Dahlén B, Bossios A, Lazarinis N, Aronsson D, Egesten A, Munir AKM, Ahlbeck L, Janson C, Škrgat S, Edelbaher N, Leuppi J, Jaun F, Rüdiger J, Pavlov N, Gianella P, Fischer R, Charbonnier F, Chaudhuri R, Smith SJ, Doe S, Fawdon M, Masoli M, Heaney L, Haitchi HM, Kurukulaaratchy R, Fulton O, Frankemölle B, Gibson T, Needham K, Howarth P, Djukanovic R, Bel E, and Hyland M
- Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic has put pressure on healthcare services, forcing the reorganisation of traditional care pathways. We investigated how physicians taking care of severe asthma patients in Europe reorganised care, and how these changes affected patient satisfaction, asthma control and future care., Methods: In this European-wide cross-sectional study, patient surveys were sent to patients with a physician-diagnosis of severe asthma, and physician surveys to severe asthma specialists between November 2020 and May 2021., Results: 1101 patients and 268 physicians from 16 European countries contributed to the study. Common physician-reported changes in severe asthma care included use of video/phone consultations (46%), reduced availability of physicians (43%) and change to home-administered biologics (38%). Change to phone/video consultations was reported in 45% of patients, of whom 79% were satisfied or very satisfied with this change. Of 709 patients on biologics, 24% experienced changes in biologic care, of whom 92% were changed to home-administered biologics and of these 62% were satisfied or very satisfied with this change. Only 2% reported worsening asthma symptoms associated with changes in biologic care. Many physicians expect continued implementation of video/phone consultations (41%) and home administration of biologics (52%)., Conclusions: Change to video/phone consultations and home administration of biologics was common in severe asthma care during the COVID-19 pandemic and was associated with high satisfaction levels in most but not all cases. Many physicians expect these changes to continue in future severe asthma care, though satisfaction levels may change after the pandemic., Competing Interests: Conflict of interest: A. Bourdin reports receiving grants or contracts outside the submitted work from AstraZeneca and Boeringher Ingelheim; and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events as well as support for attending meetings and/or travel from AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Chiesi and Amgen, outside the submitted work. Z. Csoma reports receiving honoraria for presentations from Astra/Zeneca, TEVA and Sanofi/Aventis (Hungary) outside the submitted work. E. Heffler reports receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, Sanofi-Genzyme, Regeneron, Novartis, GSK, Circassia; Stallergenes-Greer and Nestlè Purina outside the submitted work. G.W. Canonica reports receiving consulting fees from AstraZeneca GSK, Novartis, Sanofi and Stallergenes Greer; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, GSK, Novartis, Sanofi, Stallergenes Greer, Menarini, Chiesi and Mylan; participation on data safety monitoring or advisory boards for AstraZeneca, GSK, Novartis, Sanofi, Stallergenes Greer and Chiesi; all disclosures made outside the submitted work. G-J. Braunstahl reports grants or contracts from GSK, AstraZeneca and ALK Abello; consulting fees from GSK, Sanofi, ALK Abello, AstraZeneca and Novartis; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from GSK, Sanofi, ALK Abello, AstraZeneca and Novartis; and is on the scientific board of the Dutch Lung Foundation, task force Asthma NVALT and editorial board NTVAAKI; all disclosures made outside the submitted work. S. van der Sar reports receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca and GSK; and support received from ALK for attending meetings and/or travel; all disclosures made outside the submitted work. N. Nenasheva reports receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca plc., Sanofi S.A., Teva Pharmaceuticals, Novartis International AG and Chiesi Farmaceutici S.p.A., outside the submitted work. A. Bossios reports receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AZ, GSK and Teva; support for attending meetings and/or travel received from Novartis; and participation on a data safety monitoring or advisory boards for AZ, GSK, Novartis, Teva and Sanofi; and is a member of the steering Committee of SHARP, Secretary of Assembly 5 (Airway diseases, asthma, COPD and chronic cough) of the European Respiratory Society and vice-chair of Nordic Severe Asthma Network; all disclosures made outside the submitted work. D. Aronsson reports receiving grants or contracts from ALK-Abello outside the submitted work. A. Egesten reports receiving honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, outside the submitted work. L. Ahlbeck reports receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca; and participation on data safety monitoring or advisory boards for AstraZeneca, Sanofi and GSK; all disclosures made outside the submitted work. S. Škrgat reports receiving honoraria for lectures and educational events supported by GSK, AstraZeneca, Sanofi, Chiesi, Pliva Teva and Medis; and participation on advisory boards of GSK, AstraZeneca, Chiesi and Sanofi; all disclosures made outside the submitted work. N. Edelbaher reports receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from GSK, Astra Zeneca, Chiesi, Pliva Teva, Krka, Novartis, Boehringer Ingelheim and Sanofi; and participation on advisory boards of GSK, Astra Zeneca, Chiesi, Novartis and Boehringer Ingelheim; all disclosures made outside the submitted work. J. Rüdiger reports receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from the Education of Swiss Emergency physicians; and participation on a data safety monitoring board or board for Boehringer Ingelheim; and is a member of the Board of the Swiss Society of Pneumology and President of the Thorax section of the Swiss Ultrasound Society; all disclosures made outside the submitted work. N. Pavlov reports receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from GSK, Novartis and OM Pharma; support for attending meetings and/or travel received from Boehringer Ingelheim; participation on data safety monitoring or advisory boards for AstraZeneca, GSK, Novartis and Sanofi; all disclosures made outside the submitted work. P. Gianella reports participation on an advisory board for Novartis about Xolair for nasal polyps, outside the submitted work. F. Charbonnier reports receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Sanofi, Novartis, Mundipharma, AstraZeneca and GSK; participation on data safety monitoring or advisory boards for Sanofi, Novartis, Mundipharma, AstraZeneca and GSK; all disclosures made outside the submitted work. R. Chaudhuri reports receiving grants or contracts from AstraZeneca; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from GSK, AstraZeneca, Teva, Chiesi, Sanofi and Novartis; support for attending meetings and/or travel received from Chiesi, Napp, Sanofi, Boehringer, GSK and AZ; and participation on data safety monitoring or advisory boards for GSK, AstraZeneca, Teva, Chiesi and Novartis; all disclosures made outside the submitted work. S.J. Smith is supported by the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement number 831434 for Taxonomy, Targets, Treatment, and Remission; the JU receives support from the European Union's Horizon 2020 research and innovation programme, and the European Federation of Pharmaceutical Industries and Associates; all disclosures made outside the submitted work. S. Doe reports receiving support for attending meetings and/or travel from GSK and Sanofi, outside the submitted work. L. Heaney reports grants or contracts from Medimmune, Novartis UK, Roche/Genentech Inc., GlaxoSmithKline, Amgen, Genentech/Hoffman la Roche, AstraZeneca, Medimmune, Aerocrine and Vitalograph; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events for Novartis, Hoffman la Roche/Genentech Inc., Sanofi, GlaxoSmithKline, AstraZeneca, Teva and Circassia; support for attending meetings and/or travel from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Napp Pharmaceuticals; participation on data safety monitoring or advisory board for Novartis, Hoffman la Roche/Genentech Inc., Sanofi, Evelo Biosciences, GlaxoSmithKline, AstraZeneca, Teva, Theravance and Circassia; all disclosures made outside the submitted work. M. Masoli reports receiving grants or contracts from ERS SHARP to support the study “The burden of severe asthma on HRQoL across Europe”, outside the submitted work. P. Howarth is an employee of GSK. R. Djukanovic reports support for the present manuscript received from ERS, TEVA, GSK, Novartis, Sanofi and Chiesi; consulting fees from Synairgen for which the author is a co-founder and consultant and owns shares, outside the submitted work; and participation on a data safety monitoring or advisory board for Kymab (Cambridge), outside the submitted work. E. Bel reports support for the present manuscript from the ERS; grants or contracts received from GlaxoSmithKline and Teva, outside the submitted work; consulting fees received from AstraZeneca, GlaxoSmithKline, Sanofi, Sterna and Chiesi, outside the submitted work; honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events received from Teva; participation on a data safety monitoring or advisory board for AstraZeneca, outside the submitted work; and leadership or fiduciary roles, unpaid, for SHARP-CRC and RAPSODI (Dutch registry), outside the submitted work. M. Hyland reports receiving grants or contracts from TEVA; and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events for GSK; all disclosures made outside the submitted work. The remaining authors have nothing to disclose., (Copyright ©The authors 2022.)
- Published
- 2022
- Full Text
- View/download PDF
19. Health-related quality of life and disease progression in pulmonary arterial hypertension patients: a 3-year study.
- Author
-
Halimi L, Suehs CM, Marin G, Boissin C, Gamez AS, Vachier I, Molinari N, and Bourdin A
- Abstract
Objectives: The role of health-related quality of life (HRQoL) and psychological variables in pulmonary arterial hypertension (PAH) progression remains poorly quantified. We aimed to investigate the relationship between disease progression in PAH patients and HRQoL and psychological characteristics., Methods: A 3-year longitudinal cohort was initiated. Patients with stable PAH (groups I-IV ineligible for angioplasty/endarterectomy) were included (n=55). Standard clinical variables, including invasive haemodynamic parameters, were prospectively recorded. A battery of questionnaires was used to characterise the psychological status of patients upon study initiation, and HRQoL was quantified using the SF-36 Questionnaire every 3 months for 24 months, and then again at 36 months. Guideline-defined disease progression and progression-free survival were recorded for 36 months., Measurements and Main Results: Psychological distress was highly prevalent at baseline. The Physical Component Summary (PCS) and the Mental Component Summary (MCS) of the HRQoL were poor (PCS=37.13±8.18; MCS=42.42±10.88) but stable over 3 years of follow-up. Among PCS subscales, Physical Functioning (PF) (p=0.012) was identified as being independently associated with disease progression (Cox survival model), along with mean pulmonary arterial pressure (p=0.003) and cardiac output (p=0.005). Depression was the unique independent psychological characteristic associated with PF (p=0.0001)., Conclusions: PAH patients have poor HRQoL. In addition to already known criteria related to disease severity, the HRQoL PF subscale is independently associated with disease progression in PAH. This may be explained by depression., Competing Interests: Conflict of interest: L. Halimi has nothing to disclose. Conflict of interest: C.M. Suehs has nothing to disclose. Conflict of interest: G. Marin has nothing to disclose. Conflict of interest: C. Boissin has nothing to disclose. Conflict of interest: A-S. Gamez has nothing to disclose. Conflict of interest: I. Vachier has nothing to disclose. Conflict of interest: N. Molinari has nothing to disclose. Conflict of interest: A. Bourdin reports grants, personal fees, nonfinancial support and other from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis; personal fees and nonfinancial support from Teva; personal fees, nonfinancial support and other from Regeneron and Chiesi Pharmaceuticals; grants, personal fees, nonfinancial support and other from Actelion; personal fees from Gilead; nonfinancial support and other from Roche; and other from Nuvaira, all outside the submitted work., (Copyright ©The authors 2021.)
- Published
- 2021
- Full Text
- View/download PDF
20. Targeted therapy in eosinophilic chronic obstructive pulmonary disease.
- Author
-
Fieldes M, Bourguignon C, Assou S, Nasri A, Fort A, Vachier I, De Vos J, Ahmed E, and Bourdin A
- Abstract
Chronic obstructive pulmonary disease (COPD) is a common and preventable airway disease causing significant worldwide mortality and morbidity. Lifetime exposure to tobacco smoking and environmental particles are the two major risk factors. Over recent decades, COPD has become a growing public health problem with an increase in incidence. COPD is defined by airflow limitation due to airway inflammation and small airway remodelling coupled to parenchymal lung destruction. Most patients exhibit neutrophil-predominant airway inflammation combined with an increase in macrophages and CD8
+ T-cells. Asthma is a heterogeneous chronic inflammatory airway disease. The most studied subtype is type 2 (T2) high eosinophilic asthma, for which there are an increasing number of biologic agents developed. However, both asthma and COPD are complex and share common pathophysiological mechanisms. They are known as overlapping syndromes as approximately 40% of patients with COPD present an eosinophilic airway inflammation. Several studies suggest a putative role of eosinophilia in lung function decline and COPD exacerbation. Recently, pharmacological agents targeting eosinophilic traits in uncontrolled eosinophilic asthma, especially monoclonal antibodies directed against interleukins (IL-5, IL-4, IL-13) or their receptors, have shown promising results. This review examines data on the rationale for such biological agents and assesses efficacy in T2-endotype COPD patients., Competing Interests: Conflict of interest: M. Fieldes has nothing to disclose. Conflict of interest: C. Bourguignon has nothing to disclose. Conflict of interest: S. Assou has nothing to disclose. Conflict of interest: A. Nasri has nothing to disclose. Conflict of interest: A. Fort has nothing to disclose. Conflict of interest: I. Vachier has nothing to disclose. Conflict of interest: J. De Vos has nothing to disclose. Conflict of interest: E. Ahmed has nothing to disclose. Conflict of interest: A. Bourdin reports grants, personal fees, nonfinancial support and other support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis; personal fees and nonfinancial support from Teva; personal fees, nonfinancial support and other support from Regeneron, Chiesi Farmaceuticals and Actelion; personal fees from Gilead; nonfinancial support and other support from Roche; and other support from Nuvaira, all outside the submitted work., (Copyright ©ERS 2021.)- Published
- 2021
- Full Text
- View/download PDF
21. LAM is another small airway disease: lessons from microCT.
- Author
-
Bourdin A, Gamez AS, Vachier I, and Crestani B
- Subjects
- Humans, Lipopolysaccharides, X-Ray Microtomography, Airway Obstruction, Lymphangioleiomyomatosis, Pulmonary Disease, Chronic Obstructive
- Abstract
Competing Interests: Conflict of interest: A. Bourdin reports grants, personal fees and non-financial support from, and has been PI in clinical trials for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Actelion, personal fees and non-financial support from, and has been PI in clinical trials for Novartis, Regeneron and Chiesi Farmaceuticals, personal fees and non-financial support from Teva, personal fees from Gilead, non-financial support from, and has been PI in clinical trials for Roche, and has been PI in clinical trials for Nuvaira, outside the submitted work. Conflict of interest: A.S. Gamez has nothing to disclose. Conflict of interest: I. Vachier has nothing to disclose. Conflict of interest: B. Crestani has nothing to disclose.
- Published
- 2020
- Full Text
- View/download PDF
22. Careful consideration of the bleeding caused by transbronchial lung cryobiopsies.
- Author
-
Bourdin A, Romagnoli M, Gamez AS, Hireche K, Berthet JP, Mallet JP, Vachier I, Nava S, Reynaud P, Molinari N, and Suehs C
- Subjects
- Hemorrhage etiology, Humans, Lung diagnostic imaging, Lung Diseases, Interstitial
- Abstract
Competing Interests: Conflict of interest: A. Bourdin reports grants, personal fees for advisory board work, non-financial support for meeting attendance and has been investigator for AstraZeneca, GSK and Boehringer Ingelheim, personal fees for advisory board work, non-financial support for meeting attendance and has been investigator for Novartis, Chiesi Farmaceuticals and Actelion, personal fees for advisory board work and has been investigator for Teva, Regeneron and Roche, and has been investigator for Gilead, outside the submitted work. Conflict of interest: M. Romagnoli reports grants and personal fees from AstraZeneca, GSK, Roche and Novartis, grants from Boehringer, Menarini, Chiesi and Alfasigma, personal fees from Guidotti, outside the submitted work. Conflict of interest: A.S. Gamez has nothing to disclose. Conflict of interest: K. Hireche has nothing to disclose. Conflict of interest: J.P. Berthet has nothing to disclose. Conflict of interest: J.P. Mallet has nothing to disclose. Conflict of interest: I. Vachier has nothing to disclose. Conflict of interest: S. Nava has nothing to disclose. Conflict of interest: P. Reynaud has nothing to disclose. Conflict of interest: N. Molinari has nothing to disclose. Conflict of interest: C. Suehs has nothing to disclose.
- Published
- 2020
- Full Text
- View/download PDF
23. CCSP counterbalances airway epithelial-driven neutrophilic chemotaxis.
- Author
-
Knabe L, Petit A, Vernisse C, Charriot J, Pugnière M, Henriquet C, Sasorith S, Molinari N, Chanez P, Berthet JP, Suehs C, Vachier I, Ahmed E, and Bourdin A
- Subjects
- Humans, Interleukin-8 metabolism, Interleukin-8 pharmacology, Neutrophils drug effects, Pulmonary Disease, Chronic Obstructive metabolism, Recombinant Proteins pharmacology, Smoking, Sputum cytology, Bronchioles pathology, Chemotaxis, Leukocyte, Neutrophils cytology, Pulmonary Disease, Chronic Obstructive pathology, Uteroglobin pharmacology
- Abstract
Club cell secretory protein (CCSP) knockout mice exhibit increased airway neutrophilia, as found in chronic obstructive pulmonary disease (COPD). We therefore investigated whether treating COPD airway epithelia with recombinant human CCSP (rhCCSP) could dampen exaggerated airway neutrophilia.Control, smoker and COPD air-liquid interface (ALI) cultures exposed to cigarette smoke extract (CSE) were treated with and without rhCCSP. The chemotactic properties of the supernatants were assessed using Dunn chambers. Neutrophil chemotaxis along recombinant human interleukin 8 (rhIL8) gradients (with and without rhCCSP) was also determined. rhCCSP-rhIL8 interactions were tested through co-immunoprecipitation, Biacore surface plasmon resonance (SPR) and in silico modelling. The relationship between CCSP/IL8 concentration ratios in the supernatant of induced sputum from COPD patients versus neutrophilic airway infiltration assessed in lung biopsies was assessed.Increased neutrophilic chemotactic activity of CSE-treated ALI cultures followed IL8 concentrations and returned to normal when supplemented with rhCCSP. rhIL8-induced chemotaxis of neutrophils was reduced by rhCCSP. rhCCSP and rhIL8 co-immunoprecipitated. SPR confirmed this in vitro interaction (equilibrium dissociation constant=8 µM). In silico modelling indicated that this interaction was highly likely. CCSP/IL8 ratios in induced sputum correlated well with the level of small airway neutrophilic infiltration (r
2 =0.746, p<0.001).CCSP is a biologically relevant counter-balancer of neutrophil chemotactic activity. These different approaches used in this study suggest that, among the possible mechanisms involved, CCSP may directly neutralise IL8., Competing Interests: Conflict of interest: L. Knabe has nothing to disclose. Conflict of interest: A. Petit has nothing to disclose. Conflict of interest: C. Vernisse has nothing to disclose. Conflict of interest: J. Charriot has nothing to disclose. Conflict of interest: M. Pugnière has nothing to disclose. Conflict of interest: C. Henriquet has nothing to disclose. Conflict of interest: S. Sasorith has nothing to disclose. Conflict of interest: N. Molinari has nothing to disclose. Conflict of interest: P. Chanez has nothing to disclose. Conflict of interest: J-P. Berthet has nothing to disclose. Conflict of interest: C. Suehs has nothing to disclose. Conflict of interest: I. Vachier has nothing to disclose. Conflict of interest: E. Ahmed has nothing to disclose. Conflict of interest: A. Bourdin has nothing to disclose., (Copyright ©ERS 2019.)- Published
- 2019
- Full Text
- View/download PDF
24. Randomised controlled trials in severe asthma: selection by phenotype or stereotype.
- Author
-
Pahus L, Jaffuel D, Vachier I, Bourdin A, Suehs CM, Molinari N, and Chanez P
- Subjects
- Humans, Phenotype, Anti-Asthmatic Agents, Asthma
- Abstract
Competing Interests: Conflict of interest: L. Pahus has nothing to disclose. Conflict of interest: D. Jaffuel has nothing to disclose. Conflict of interest: I. Vachier has nothing to disclose. Conflict of interest: A. Bourdin has been an investigator in clinical trials for and received grants, personal fees and non-financial support from GSK, has been an investigator in clinical trials for and received grants and personal fees from AstraZeneca, Boehringer Ingelheim, Novartis, Chiesi Farma and Teva, has been an investigator in clinical trials for PneumRx, has been an investigator in clinical trials for and received personal fees from Actelion, and received grants from Merck, outside the submitted work. Conflict of interest: C.M. Suehs has nothing to disclose. Conflict of interest: N. Molinari has nothing to disclose. Conflict of interest: P. Chanez reports grants and personal fees for consultancy, advisory board work and lectures from Almirall, Boehringer Ingelheim, Centocor, GSK, AstraZeneca, Novartis, Teva, Chiesi, ALK and Boston Scientific, and grants from AMU, outside the submitted work.
- Published
- 2019
- Full Text
- View/download PDF
25. Mortality: a neglected outcome in OCS-treated severe asthma.
- Author
-
Bourdin A, Molinari N, Vachier I, Pahus L, Suehs C, and Chanez P
- Subjects
- Administration, Oral, Adult, Aged, Female, Humans, Male, Middle Aged, Prospective Studies, Adrenal Cortex Hormones administration & dosage, Anti-Asthmatic Agents administration & dosage, Asthma drug therapy, Asthma mortality
- Abstract
Competing Interests: Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com
- Published
- 2017
- Full Text
- View/download PDF
26. Human bronchial epithelium orchestrates dendritic cell activation in severe asthma.
- Author
-
Gras D, Martinez-Anton A, Bourdin A, Garulli C, de Senneville L, Vachier I, Vitte J, and Chanez P
- Subjects
- Adult, Aged, Aged, 80 and over, Cells, Cultured, Coculture Techniques, Cytokines immunology, Female, Humans, Interleukin-33 immunology, Interleukin-8 immunology, Male, Middle Aged, Th2 Cells immunology, Thymic Stromal Lymphopoietin, Asthma immunology, Dendritic Cells immunology, Epithelial Cells immunology
- Abstract
The innate immune response is impaired in asthma, with increased epithelial release of C-X-C motif chemokine ligand (CXCL)8, interleukin (IL)-33 and thymic stromal lymphopoietin (TSLP). We hypothesised that dendritic cells might modulate the hyperresponsive epithelium in severe asthma.For this purpose, we investigated epithelial-dendritic crosstalk in normal and diseased conditions, and because ultrafine particulate matter may affect asthmatic airways, we investigated its impact on this crosstalk. Air-liquid interface cultures of human bronchial epithelial cells (HBEC) of control subjects (cHBEC) or severe asthma patients (saHBEC) were co-cultured with monocyte-derived dendritic cells (moDC).Increased release of CXCL8, TSLP and IL-33 from saHBEC contrasted with cHBEC producing CXCL10 and CCL2. Regarding moDC activation, saHBEC co-cultures induced only upregulation of CD86 expression, while cHBEC yielded full moDC maturation with HLA-DR, CD80, CD86 and CD40 upregulation. Particulate matter stimulation of HBEC had no effect on cHBEC but stimulated CXCL8 and IL-33 release in saHBEC. Particulate matter impaired epithelium signalling (TSLP, IL-33 and CXCL8) in saHBEC co-cultures despite C-C chemokine ligand 2 induction.Crosstalk between HBEC and moDC can be established in vitro , driving a T1-type response with cHBEC and a T2-type response with saHBEC. Normal or asthmatic status of HBEC differentially shapes the epithelial-dendritic responses. We conclude that control moDC cannot rescue the hyperresponsive airway epithelium of severe asthmatics., (Copyright ©ERS 2017.)
- Published
- 2017
- Full Text
- View/download PDF
27. Future treatment for asthma.
- Author
-
Charriot J, Vachier I, Halimi L, Gamez AS, Boissin C, Salama M, Cucu-Jarjour A, Ahmed E, and Bourdin A
- Subjects
- Animals, Asthma metabolism, Asthma physiopathology, Biomarkers metabolism, Forecasting, Humans, Lung metabolism, Lung physiopathology, Phenotype, Anti-Asthmatic Agents therapeutic use, Asthma drug therapy, Drug Discovery trends, Lung drug effects, Molecular Targeted Therapy trends, Precision Medicine trends
- Abstract
The landscape of asthma has considerably changed after 40 years of inhaled corticosteroid development and nearly 20 years since the first monoclonal antibodies (mAbs) were approved. New members of pharmacological families and more effective drug-delivery devices have been designed but the proportion of uncontrolled patients, unfortunately, remains stable. The most promising treatments now rely on targeted therapies that encourage the improvement of the characterisation of our patients. These clinical (phenotype) or new biological (endotype) tools lead to palpable personalised medicine. This review examines not only the future of mAbs and other new ways of treating asthma but also describes futuristic views based on the paradigm shifts that are ready to occur., (Copyright ©ERS 2016.)
- Published
- 2016
- Full Text
- View/download PDF
28. Computed tomography quantification of airway remodelling in normal ageing subjects: a cross-sectional study.
- Author
-
Bommart S, Marin G, Bourdin A, Revel MP, Klein F, Hayot M, Vachier I, Chanez P, Picot MC, Mercier J, Molinari N, and Vernhet-Kovacsik H
- Subjects
- Aged, Aged, 80 and over, Analysis of Variance, Cross-Sectional Studies, Female, Healthy Volunteers, Humans, Male, Middle Aged, Regression Analysis, Spirometry, Aging physiology, Airway Remodeling physiology, Respiratory Function Tests, Tomography, X-Ray Computed methods
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.